Can online therapy calm BRCA1/2 women's fear of cancer return?
NCT ID NCT06817694
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a 4-week online cognitive-behavioral therapy (CBT) program for women with BRCA1/2 mutations who have finished cancer treatment and still worry a lot about cancer coming back. Researchers will compare those who get therapy right away to those on a waitlist, measuring fear levels, anxiety, and quality of life. The goal is to see if this adapted therapy helps and if the effects last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cognitive-behavioral group therapy
- What this could lead to
- If successful, this could provide an effective, accessible online therapy to help women with BRCA1/2 mutations manage fear of cancer recurrence and improve quality of life.
- What could go wrong
- This is a relatively small, early-stage trial comparing therapy to a waitlist, not a placebo. The therapy may not work for everyone, and benefits might not last long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA2 MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Québec-Université Laval
RECRUITINGQuébec, Quebec, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a new drug combo revive Immunotherapy's power against resistant tumors?